arrow
J

Jamie Orengo

regeneron pharmaceuticals
H指数:20
被引数:2,047

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Type-2-Inflammatory-Diseases Share Comorbidities, Molecular Signatures, IL4/IL13 Genetics, and Response to IL4/IL13 Blockade

2型炎症性疾病共享共病、分子特征、IL4/IL13遗传学以及对IL4/IL13阻断剂的反应

2026-05-140
OAAI
The IL-33 and IL-4Rα blocking antibodies itepekimab and dupilumab modulate both distinct and common inflammatory mediators in asthma

伊特佩克单抗(itepekimab)和杜匹鲁单抗(dupilumab)这两种针对IL-33和IL-4Rα的阻断抗体,能够调节哮喘中既独特又共同的炎症介质。

2025-10-290
PRE
Dupilumab as an Adjunct to Oral Immunotherapy in Pediatric Patients With Peanut Allergy

Dupilumab作为花生过敏患儿口服免疫治疗的辅助手段

2024-12-140
PRE
Efficacy and Safety of Dupilumab in Children With Peanut Allergy: A Multicenter, Open-Label, Phase II Study
2024-12-140
OAAI
Monoclonal antibodies against the spike protein alter the endogenous humoral response to SARS-CoV-2 vaccination and infection
2024-11-060
PRE
A therapeutic strategy to target distinct sources of IgE and durably reverse allergy
2023-12-1311
PRE